Assessment of Enhanced Recovery After Surgery Implementation at Pediatric Surgery Practices in Mainland China

October 22, 2022 updated by: Weibing Tang

Assessment of Enhanced Recovery After Surgery Implementation at Pediatric Surgery Practices in Mainland China: Based on a Survey of Performing Congenital Biliary Dilatation Operations

Enhanced recovery after surgery (ERAS) is a new mode to optimize perioperative management, the core of which is to reduce perioperative physiological and psychological trauma and stress damage, and accelerate postoperative rehabilitation. ERAS has been gradually introduced in pediatric surgery in recent years, however, there are limited reports on its overall implementation. We aimed to determine the popularity of ERAS among pediatric populations in mainland China.

Study Overview

Status

Completed

Conditions

Detailed Description

The application of ERAS in children with congenital biliary dilatation (CBD) was investigated. A total of 31 province-level administrative regions in mainland China were involved and each of them had at least one participating center. A questionnaire was designed to assess the baseline adherence of 17 recovery elements and chief pediatric surgeons at each center were invited to complete.

Study Type

Observational

Enrollment (Actual)

66

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Jiangsu
      • Nanjing, Jiangsu, China
        • NJMU

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

chief pediatric surgeons at each center

Description

Inclusion Criteria:

  • chief pediatric surgeons at each center

Exclusion Criteria:

  • Incomplete questionnaire

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
This investigation was conducted on chief surgeons at each center.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Element adherence
Time Frame: immediately after all the questionnaires are collected
Adherence to an element was determined if the frequency of practice reached specific thresholds as defined.
immediately after all the questionnaires are collected

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Factors associated with baseline ERAS utilization
Time Frame: immediately after all the questionnaires are collected
Factors associated with baseline ERAS utilization
immediately after all the questionnaires are collected

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Barriers to implementation
Time Frame: immediately after all the questionnaires are collected
Barriers to implementation
immediately after all the questionnaires are collected
Outcomes of concern
Time Frame: immediately after all the questionnaires are collected
Outcomes of concern
immediately after all the questionnaires are collected

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Hua Xie, M.M., Department of pediatric Surgery, Children's Hospital of Nanjing Medical University, Nanjing, China.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2021

Primary Completion (Actual)

July 1, 2022

Study Completion (Actual)

July 21, 2022

Study Registration Dates

First Submitted

July 25, 2022

First Submitted That Met QC Criteria

October 22, 2022

First Posted (Actual)

October 25, 2022

Study Record Updates

Last Update Posted (Actual)

October 25, 2022

Last Update Submitted That Met QC Criteria

October 22, 2022

Last Verified

October 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • NanjingCH13170

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe